Related Experiment Video
Updated: Aug 7, 2026

10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Günther Tulip filter retrievability multicenter study including CT follow-up: final report
Hanno Hoppe1, Charles W Nutting, H Robert Smouse
1Dotter Interventional Institute, Oregon Health Science University, Portland 97239-3098, USA.
Journal of Vascular and Interventional Radiology : JVIR
|June 17, 2006
Summary
Retrieval of the Günther Tulip inferior vena cava (IVC) filter was safe and effective. This study found no recurrent thromboembolic events or IVC/jugular vein damage after filter removal.
Area of Science:
- Vascular Surgery
- Interventional Radiology
- Cardiovascular Medicine
Background:
- Inferior vena cava (IVC) filters are used to prevent pulmonary embolism (PE) and deep vein thrombosis (DVT).
- Temporary IVC filters, like the Günther Tulip, require safe and effective retrieval methods.
- Assessing retrieval outcomes is crucial for patient safety and treatment efficacy.
Purpose of the Study:
- To evaluate the safety and effectiveness of retrieving the Günther Tulip IVC filter.
- To assess complications associated with Günther Tulip filter retrieval.
- To determine the incidence of recurrent thromboembolic events and vascular damage post-retrieval.
Main Methods:
- A multicenter, prospective, single-arm study involving 41 patients who received 42 Günther Tulip filters.
- Indications for filter placement included prophylaxis, PE, and DVT.
- Follow-up included contrast-enhanced CT, jugular vein ultrasonography, and clinical assessment at 3 months post-retrieval.
Main Results:
- The filter retrieval rate was 57% (23 of 41 patients).
- Technical and clinical success rates for filter retrieval were 100%.
- No acute complications from retrieval were observed; no recurrent PE, DVT, or vascular damage at 3-month follow-up.
Conclusions:
- Retrieval of the Günther Tulip IVC filter is a safe procedure.
- The retrieval process was associated with a high success rate and no significant complications.
- No recurrent thromboembolic events or vascular damage were noted at 3-month follow-up, indicating long-term safety.